Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions

Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review | BMC Medicine | Full Text
 

Conclusions

Most of the drugs that affect monoamine neurotransmitters licensed for the treatment of obesity over the past 65 years have been withdrawn because of adverse reactions.